Myrobalan Therapeutics is a preclinical biotech developing orally bioavailable, brain‑penetrant small‑molecule neurorestorative therapies—GPR17 antagonist, CSF1R and TYK2 inhibitors—targeting remyelination and neuroinflammation in CNS diseases.
myrotx.comPart of: Boston tech scene from Fundable